Close

Thermo Fisher supports gene developers with new AAV manufacturing solutions

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Thermo Fisher Scientific has expanded its gene therapy portfolio to include a new media panel, gene kit and advanced purification resins to support gene therapy developers seeking to rapidly and efficiently scale adeno-associated viral (AAV) production.

AAV, which has become the preferred viral vector for delivering gene therapies, is difficult to scale, particularly during the purification process.

Thermo has responded to the challenge with “focused” investment into new solutions that produce higher quality viral vectors and simplify the purification process, thereby resulting in higher yield AAV production.

The Gibco Viral Vector HEK Media Panel covers a broad variety of HEK293 cell types and is not tied to specific transfection reagents or techniques. Its ready-to-use formulations will help
AAV developers identify an optimal formulation for their target cell line.

The Applied Biosystems resDNASEQ Quantitative Plasmid DNA – Kanamycin Resistance Gene Kit offers an all-in-one solution for precise and rapid measurement of residual plasmid DNA.
Thermo Scientific POROS Capture Select AAV affinity purification resins can, according to the company, significantly improve downstream processing of viral vectors by reducing purification steps and offering scalability to maximise process consistency, efficiency and productivity.

Capture Select lig and technology, combined with the large pore structure of the POROS beads, enables efficient purification of large biomolecules such as viral vectors.

“Our expanding gene therapy portfolio is designed for a smooth ramp-up to clinical production and we have made focused investments to ensure we stay ahead of commercial demand,” said Betty Woo, vice president and general manager, cell and gene therapy at
Thermo Fisher Scientific.

Latest stories

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back